RemeGen Allocates Additional RMB50.00 Million to HTSC Wealth Management Products, Raising Total Deployment to RMB538.00 Million

Bulletin Express18:03

RemeGen Co., Ltd. (RemeGen) disclosed that on 20 May 2026 it signed two new agreements—HTSC Wealth Management Product Agreement No. 7 and No. 8—with Huatai Securities Co., Ltd. (HTSC), committing a further RMB20.00 million and RMB30.00 million, respectively, of idle self-owned funds to medium-risk wealth management products.

• Agreement No. 7: “Xiamen Trust – Hongyun Xiangtai No. 11 Asset Management Trust Product” – Product type: Fixed-income collective fund trust plan – Principal: RMB20.00 million – Tenor: ~36 months; early termination at trustee’s discretion – Risk rating: Medium; yield tied to market performance – Investment focus: Consumer loan assets via revolving purchase

• Agreement No. 8: “Shengxinxiang – Huatai WEFUND Private FOF 1067 Separate Asset Management Plan” – Product type: Mixed private FOF – Principal: RMB30.00 million – Tenor: 10 years with subscriber-driven exit; early termination at administrator’s discretion – Risk rating: Medium; yield tied to market performance – Investment focus: Financial products and cash-type assets

Including the latest tranche, RemeGen has channelled RMB538.00 million into eight HTSC-managed products since 14 May 2026: • 14 May: RMB60.00 million (No. 1), RMB75.00 million (No. 2), RMB102.00 million (No. 3), RMB216.00 million (No. 4) • 19 May: RMB15.00 million (No. 5), RMB20.00 million (No. 6) • 20 May: RMB20.00 million (No. 7), RMB30.00 million (No. 8)

The Board previously authorised up to RMB2.50 billion for cash management using idle funds at its 36th meeting on 27 March 2026. Post-transaction, around RMB1.96 billion of the approved limit remains unutilised.

Under Hong Kong Listing Rule 14.22, the eight agreements—concluded with the same financial institution within a 12-month period—are aggregated. As one of the applicable percentage ratios exceeds 5% but all remain below 25%, the series of purchases constitutes a discloseable transaction, triggering reporting and announcement obligations under Chapter 14 of the Listing Rules.

RemeGen states that the medium-risk products, offering returns above comparable bank time deposits, aim to enhance the yield on its surplus cash while maintaining prudent risk control. HTSC is an independent third-party securities company listed on both the Shanghai and Hong Kong stock exchanges, providing wealth management and other financial services.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment